GGHC
NVAX icon

Gilder Gagnon Howe & Co’s Novavax NVAX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,791
Closed -$41K – 303
2017
Q3 		$41K Buy
+1,791
New +$40.1K ﹤0.01% 275
2015
Q3 		– Sell
-5,385
Closed -$1.2M – 274
2015
Q2 		$1.2M Sell
5,385
-91
-2% -$16K 0.02% 208
2015
Q1 		$906K Sell
5,476
-195
-3% -$31.7K 0.01% 207
2014
Q4 		$673K Sell
5,671
-175
-3% -$18.3K 0.01% 214
2014
Q3 		$488K Buy
5,846
+41
+0.7% +$3.71K 0.01% 228
2014
Q2 		$536K Buy
5,805
+68
+1% +$5.98K 0.01% 242
2014
Q1 		$520K Buy
5,737
+305
+6% +$34.1K 0.01% 226
2013
Q4 		$556K Buy
+5,432
New +$384K 0.01% 220

Other funds holding NVAX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gilder Gagnon Howe & Co's NVAX Position: Q4 2017 in Review

Gilder Gagnon Howe & Co sold out of Novavax (NVAX) in Q4 2017, closing a stake of 1,791 shares — an estimated $41K sold.

Gilder Gagnon Howe & Co first reported a position in NVAX in Q4 2013 and held it in 8 quarters. The position peaked at $1.2M in Q2 2015. 134 funds tracked by Wall St. Rank hold NVAX as of Q4 2017.

  • Gilder Gagnon Howe & Co reported no remaining Novavax position as of Q4 2017 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 1,791 Novavax shares in Q4 2017, an estimated $41K.
  • Gilder Gagnon Howe & Co first reported a position in Novavax in Q4 2013 and held it in 8 quarters.
  • Gilder Gagnon Howe & Co's Novavax position peaked at $1.2M in Q2 2015.
  • 134 funds tracked by Wall St. Rank held Novavax as of Q4 2017.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2017, filed 31 Jan 2018.